Valeria Belleudi, Alessandro C Rosa, Marco Finocchietti, Francesca R Poggi, Maria Lucia Marino, Marco Massari, Stefania Spila Alegiani, Lucia Masiero, Andrea Ricci, Gaia Bedeschi, Francesca Puoti, Massimo Cardillo, Silvia Pierobon, Maurizio Nordio, Eliana Ferroni, Martina Zanforlini, Giuseppe Piccolo, Olivia Leone, Stefano Ledda, Paolo Carta, Donatella Garau, Ersilia Lucenteforte, Marina Davoli, Antonio Addis
The goal of post-transplant immunosuppressive drug therapy is to prevent organ rejection while minimizing drug toxicities. In clinical practice, a multidrug approach is commonly used and involves drugs with different mechanisms of action, including calcineurin inhibitors (CNI) (tacrolimus or cyclosporine), antimetabolite (antimet) (mycophenolate or azathioprine), inhibitors of mechanistic target of rapamycin (mTOR) (sirolimus or everolimus), and/or steroids. Although evidence based on several randomized clinical trials is available, the optimal immunosuppressive therapy has not been established and may vary among organ transplant settings...
2022: Frontiers in Pharmacology